Skip to content

Effect of atorvastatin gel on GCF cytokines of patients with chronic periodontitis

Evaluation of the effect of local Atorvastatin gel application on levels of gingival crevicular fluid cytokines IL-17 and TGF-ß in patients with chronic periodontitis and comparison with placebo

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20150210021029N5
Enrollment
20
Registered
2021-06-09
Start date
2021-05-22
Completion date
Unknown
Last updated
2021-06-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic periodontitis. Chronic periodontitis

Interventions

Intervention 1: Intervention group: After the primary sampling, scaling and oral hygiene education, by split-mouth protocol for each patient in one quadrant (which will be selected by randomization by

Sponsors

Esfahan University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
30 Years to 60 Years

Inclusion criteria

Inclusion criteria: Having mild to moderate chronic periodontitis (bone crest distance from CEJ>2, Clinical Attachment Loss=3) Having at least 20 teeth Not having a bridge, crown, or orthodontic braces in the gel application area Having at least 2 pockets with 4-7mm of probing depth and CAL of equal to or greater than 3mm

Exclusion criteria

Exclusion criteria: Having systemic diseases Nonconformity of the prescribed diet Pregnancy and lactation Showing coronavirus disease symptoms or similar symptoms Receiving periodontal treatment and/or usage of antibiotics during 1 month before treatment Presence of aggressive periodontitis and systemic conditions affecting the periodontal condition Malnutrition and impaired immune status Smoking Using statins or allergy to them Using drugs that affect oral tissues Use of antibiotics Use of cholesterol-lowering drugs such as statins

Design outcomes

Primary

MeasureTime frame
Mean IL-17 level. Timepoint: At baseline (before the intervention) and at 3 months after gel application. Method of measurement: ELISA Il-17 Human Kit.;Mean TGF-ß level. Timepoint: At baseline (before the intervention) and at 3 months after gel application. Method of measurement: ELISA TGF-ß Human Kit.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSima Kiani

Esfahan University of Medical Sciences

Simakiani@dnt.mui.ac.ir+98 31 3792 5542

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026